Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugh Watson

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Hepatology (Baltimore, Md.)|November 25, 2015
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patientsLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
BMC Gastroenterology|July 27, 2016
Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort studyPeter Jepsen, Jakob Christensen, Karin Weissenborn, et al.
Clinics and Research in Hepatology and Gastroenterology|August 23, 2024
The CIRrhotic Ascites Severity (CIRAS) model predicts hepatic hydrothorax at all stages of ascitesRasmus Hvidbjerg Gantzel, Thomas Deleuran, Hendrik Vilstrup, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Diabetes does not increase infection risk or mortality following an infection in patients with cirrhosis and ascitesLars Bossen, Gitte A Dam, Hendrik Vilstrup, et al.
Alimentary Pharmacology & Therapeutics|December 27, 2018
Quality of life measures predict mortality in patients with cirrhosis and severe ascitesStewart Macdonald, Peter Jepsen, Laith Alrubaiy, et al.
Metabolic Brain Disease|March 7, 2013
Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy developmentHugh Watson, Peter Jepsen, Florence Wong, et al.
Research in Sports Medicine (Print)|March 22, 2014
Surface electromyographic activities of upper body muscles during high-intensity cycle ergometryMarie Clare McCormick, Hugh Watson, Alan Simpson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2018
Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascitesGitte Dam, Hendrik Vilstrup, Per Kragh Andersen, et al.
Scandinavian Journal of Gastroenterology|October 15, 2019
QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascitesKonstantin Kazankov, Henrik Kjaerulf Jensen, Hugh Watson, et al.
Hepatology (Baltimore, Md.)|May 30, 2008
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trialPere Ginès, Florence Wong, Hugh Watson, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Hepatology (Baltimore, Md.)|November 25, 2015
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patientsLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
BMC Gastroenterology|July 27, 2016
Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort studyPeter Jepsen, Jakob Christensen, Karin Weissenborn, et al.
Clinics and Research in Hepatology and Gastroenterology|August 23, 2024
The CIRrhotic Ascites Severity (CIRAS) model predicts hepatic hydrothorax at all stages of ascitesRasmus Hvidbjerg Gantzel, Thomas Deleuran, Hendrik Vilstrup, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Diabetes does not increase infection risk or mortality following an infection in patients with cirrhosis and ascitesLars Bossen, Gitte A Dam, Hendrik Vilstrup, et al.
Alimentary Pharmacology & Therapeutics|December 27, 2018
Quality of life measures predict mortality in patients with cirrhosis and severe ascitesStewart Macdonald, Peter Jepsen, Laith Alrubaiy, et al.
Metabolic Brain Disease|March 7, 2013
Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy developmentHugh Watson, Peter Jepsen, Florence Wong, et al.
Research in Sports Medicine (Print)|March 22, 2014
Surface electromyographic activities of upper body muscles during high-intensity cycle ergometryMarie Clare McCormick, Hugh Watson, Alan Simpson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2018
Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascitesGitte Dam, Hendrik Vilstrup, Per Kragh Andersen, et al.
Scandinavian Journal of Gastroenterology|October 15, 2019
QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascitesKonstantin Kazankov, Henrik Kjaerulf Jensen, Hugh Watson, et al.
Hepatology (Baltimore, Md.)|May 30, 2008
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trialPere Ginès, Florence Wong, Hugh Watson, et al.
Pageof 6